The risk of congestive heart failure: sobering lessons from the framingham heart study

This review highlights recent contributions of the Framingham Heart Study to our understanding of the epidemiology of congestive heart failure (CHF). Given its uniform criteria for the diagnosis of CHF and its long duration of follow-up, the Framingham study has had a unique perspective on the short- and long-term risk of developing CHF, its predisposing risk factors, and its prognosis in a general, community-based population. Some recent studies from Framingham have provided important insights on CHF: the lifetime risk is estimated to be 20% for men and women; hypertension is the most important modifiable risk factor, with a population-attributable risk of CHF of 59% for women and 39% for men; a clinical prediction rule for development of CHF has recently been published; and the prognosis after development of CHF is grim, with a median survival of 1.7 years in men and 3.2 years in women.

[1]  D. Levy,et al.  Survival After the Onset of Congestive Heart Failure in Framingham Heart Study Subjects , 1993, Circulation.

[2]  K. Bailey,et al.  Congestive heart failure in the community: trends in incidence and survival in a 10-year period. , 1999, Archives of internal medicine.

[3]  K. Bailey,et al.  Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. , 1998, Circulation.

[4]  R A Levine,et al.  Prevalence and clinical outcome of mitral-valve prolapse. , 1999, The New England journal of medicine.

[5]  W. Kannel,et al.  The natural history of congestive heart failure: the Framingham study. , 1971, The New England journal of medicine.

[6]  D. Levy,et al.  Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. , 1999, Journal of the American College of Cardiology.

[7]  R. Goldberg,et al.  Assessing the population burden from heart failure: need for sentinel population-based surveillance systems. , 1999, Archives of internal medicine.

[8]  R. Vasan,et al.  The progression from hypertension to congestive heart failure. , 1996, JAMA.

[9]  Daniel Levy,et al.  Lifetime risk of developing coronary heart disease , 1999, The Lancet.

[10]  J. Murabito,et al.  Lifetime Risk for Developing Congestive Heart Failure: The Framingham Heart Study , 2002, Circulation.

[11]  D. Levy,et al.  Profile for estimating risk of heart failure. , 1999, Archives of internal medicine.

[12]  W. Kannel.  Epidemiological aspects of heart failure. , 1989, Cardiology clinics.

[13]  D. Levy,et al.  Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. , 1997, The New England journal of medicine.

[14]  D. Levy,et al.  Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). , 1991, The American journal of cardiology.

[15]  D. Levy,et al.  The epidemiology of heart failure: the Framingham Study. , 1993, Journal of the American College of Cardiology.

[16]  R B D'Agostino,et al.  Lifetime risk of dementia and Alzheimer's disease , 1997, Neurology.

[17]  J. Remes,et al.  Incidence of heart failure in eastern Finland: a population-based surveillance study. , 1992, European heart journal.

[18]  E. Braunwald.  Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. , 1997, The New England journal of medicine.